On a consolidated basis, the company witnessed sales growth of 6.8% YoY to | 683.5 crore (vs. I-direct estimate: | 700.1 crore) mainly led by double digit growth in EAP, Europe & Americas region. Revenues from the AMESA witnessed de-growth of 1.2% to | 233.7 crore. Europe revenues grew 11.8% to | 147.9 crore. EAP & Americans region witnessed growth of 16.6% & 11.2% to | 184.7 crore and | 143.5 crore respectively. Within Amesa, India business adversely impacted by low client offtake, pharma regulations and...